Scope:
Keywords:
Update

News about companies and Biogen

52 days ago

Analyse the news about companies and Biogen from multiple sources, get visualizations or extract the entire dataset.

Related dashboards:

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Read on: CNBC News link
52d ago

Sage Therapeutics Jumps on Biogen's $469 Million Takeover Offer

Read on: Bloomberg link
83d ago

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

Read on: CNBC News link
157d ago

Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction

Read on: CNBC News link
236d ago

Biogen is buying up an immune drug developer for $1.8 billion

Read on: Quartz link
319d ago

Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup

Read on: Quartz link
345d ago

Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up

Read on: CNBC News link
347d ago

Stocks making the biggest moves midday: JetBlue Airways, Shopify, Biogen and more

Read on: CNBC News link
418d ago

Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

Read on: CNBC News link
418d ago

Biogen dumps dubious Alzheimer's drug after profit-killing FDA scandal

Read on: Ars Technica link
431d ago

Biogen to stop selling controversial Alzheimer's drug Aduhelm

Read on: NBC News link
431d ago

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

Read on: CNBC News link
431d ago

Biogen Quits Controversial Alzheimer's Drug Aduhelm

431d ago

Biogen Plans to Shut Down Its Controversial Alzheimer's Drug Aduhelm

Read on: Time link
431d ago

Biogen scraps controversial Alzheimer's drug Aduhelm

Read on: CBS link
431d ago

Biogen to shut down its controversial Alzheimer's drug Aduhelm

431d ago

Biogen to cease production of controversial Alzheimer's drug

Read on: Politico link
431d ago

Here are Thursday's biggest analyst calls: Nvidia, Rivian, Apple, AMD, Amazon, Biogen, DataDog, Bumble & more

Read on: CNBC News link
486d ago

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Read on: ABC News link
558d ago

Dataset

Extract all news on this scope:

Analysis

See the trend on this scope:

Evolution through time

Sources analysis:

Distribution of sources in the news

Sections analysis:

Distribution of sections in the news

Current sentiment polarity: neutral with a score of 0.06

neutral 42%
positive 32%
negative 26%

Sentiment polarity through time